Research ArticleAccepted Article
Comparative persistence on methotrexate and TNF inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
Michael D. George, Joshua F. Baker and Alexis Ogdie
The Journal of Rheumatology September 2019, jrheum.190299; DOI: https://doi.org/10.3899/jrheum.190299
Michael D. George
From the University of Pennsylvania, Division of Rheumatology; Philadelphia Veterans Affairs Medical Center, Division of Rheumatology; University of Pennsylvania, Perelman School of Medicine, Department of Biostatistics Epidemiology and Informatics. Sources of support: This worked was supported by the McCabe Foundation; the Rheumatology Research Foundation Scientist Development Award to MG; the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health [grant numbers K23 AR073931-01 to MG and R01 AR072363 to AO]; and the United States Veterans Affairs Clinical Science Research & Development [grant number I01 CX001703 to JB]. Michael George: research grant from Bristol-Myers Squibb, consulting fees from AbbVie (<$10,000) Joshua Baker: consulting fees from Bristol-Myers Squibb and Corrona (<$10,000 each). Alexis Ogdie: consulting fees from Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda (<$10,000 each) and research grant funding to the University of Pennsylvania from Novartis and Pfizer. Address correspondence to Michael D. George, 5 White Building, 3400 Spruce St, Philadelphia, PA 19104. E-mail: Michael.george@uphs.upenn.edu
Joshua F. Baker
From the University of Pennsylvania, Division of Rheumatology; Philadelphia Veterans Affairs Medical Center, Division of Rheumatology; University of Pennsylvania, Perelman School of Medicine, Department of Biostatistics Epidemiology and Informatics. Sources of support: This worked was supported by the McCabe Foundation; the Rheumatology Research Foundation Scientist Development Award to MG; the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health [grant numbers K23 AR073931-01 to MG and R01 AR072363 to AO]; and the United States Veterans Affairs Clinical Science Research & Development [grant number I01 CX001703 to JB]. Michael George: research grant from Bristol-Myers Squibb, consulting fees from AbbVie (<$10,000) Joshua Baker: consulting fees from Bristol-Myers Squibb and Corrona (<$10,000 each). Alexis Ogdie: consulting fees from Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda (<$10,000 each) and research grant funding to the University of Pennsylvania from Novartis and Pfizer. Address correspondence to Michael D. George, 5 White Building, 3400 Spruce St, Philadelphia, PA 19104. E-mail: Michael.george@uphs.upenn.edu
Alexis Ogdie
From the University of Pennsylvania, Division of Rheumatology; Philadelphia Veterans Affairs Medical Center, Division of Rheumatology; University of Pennsylvania, Perelman School of Medicine, Department of Biostatistics Epidemiology and Informatics. Sources of support: This worked was supported by the McCabe Foundation; the Rheumatology Research Foundation Scientist Development Award to MG; the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health [grant numbers K23 AR073931-01 to MG and R01 AR072363 to AO]; and the United States Veterans Affairs Clinical Science Research & Development [grant number I01 CX001703 to JB]. Michael George: research grant from Bristol-Myers Squibb, consulting fees from AbbVie (<$10,000) Joshua Baker: consulting fees from Bristol-Myers Squibb and Corrona (<$10,000 each). Alexis Ogdie: consulting fees from Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda (<$10,000 each) and research grant funding to the University of Pennsylvania from Novartis and Pfizer. Address correspondence to Michael D. George, 5 White Building, 3400 Spruce St, Philadelphia, PA 19104. E-mail: Michael.george@uphs.upenn.edu
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Accepted manuscript
Comparative persistence on methotrexate and TNF inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
Michael D. George, Joshua F. Baker, Alexis Ogdie
The Journal of Rheumatology Sep 2019, jrheum.190299; DOI: 10.3899/jrheum.190299